Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2024-09-03 Share Issue/Capital Cha…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Cleansing Notice 2 pages 213.7KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX release dated 4 September 2024, announcing the issue of 87,999,186 fully paid ordinary shares as part settlement of deferred consideration for a Licence Agreement. It references section 708A(5)(e) of the Corporations Act 2001, which relates to disclosure notices for share issues without a prospectus. The document is short (3800 characters) and primarily serves as a formal announcement of a share issuance event. There is no financial data, report, or detailed analysis included. This fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other filing types.
2024-09-03 English
Imugene Webinar - Azer-cel Trial Update 2 pages 227.9KB
Investor Presentation Classification · 90% confidence The document is an ASX announcement about an upcoming investor webinar to discuss new clinical trial data. It includes details about the webinar date, registration link, and contact information. There is no substantive financial data, no detailed financial report, nor any regulatory filing or certification. The document is short (3551 characters) and serves as an announcement for an investor presentation event rather than the presentation itself or a financial report. Therefore, it fits best as an Investor Presentation (IP) announcement or invitation. Given the content and purpose, the classification is Investor Presentation (IP).
2024-09-02 English
Three Complete Responses in Azer-Cel Phase 1b Trial 6 pages 347.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing clinical trial results for a Phase 1b trial of a cancer therapy drug (azer-cel). It provides specific data on patient cohorts, response rates, and ongoing trial status. The document is not a full financial report, audit, or regulatory filing but rather a clinical trial update and progress announcement. It is not a transcript, management report, or investor presentation. The content focuses on clinical trial results and ongoing development plans, typical of a Capital/Financing Update or clinical progress announcement. Given the nature of the announcement and its focus on trial results and development progress, the most appropriate classification is Capital/Financing Update (CAP).
2024-09-01 English
Appendix 4E and Annual Report 113 pages 6.1MB
Regulatory Filings
2024-08-29 English
Corporate Governance Statement 2024 and Appendix 4G 26 pages 728.0KB
Governance Information Classification · 95% confidence The document is titled 'Corporate Governance Statement 2024' and is prepared in accordance with ASX Listing Rule 4.10.3 for the financial year ended 30 June 2024. It discusses the company's governance framework, board structure, ethics, risk management, and related governance policies. It references the Annual Report and other governance documents but does not contain financial statements or detailed financial performance data itself. The content focuses on governance principles, board responsibilities, committees, and policies rather than financial results or audit opinions. Therefore, this document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-08-29 English
Imugene ESG Report 2024 20 pages 2.9MB
Regulatory Filings
2024-08-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.